Likely effective in management of moderate-to-severe psoriasis.
Agent specifically binding IL-17
Agent specifically binding IL-23
Both
Neither
Risankizumab (Skyrizi):
Fully human immunoglobulin (IgG) monoclonal antibody.
This agent targets the p19 subunit of IL-23
Both
Neither
Guselkumab adverse effects/effects:
Elevated risk of bacterial, viral and fungal infections.
Injection site reactions
Both
Neither
Prominent in common side effects following guselkumab administration include/includes:
Upper respiratory tract infections
Herpes simplex infections
Gastroenteritis
All of the above
IL-23 selective inhibition stems from his central role in chronic immune disease pathology generally and of psoriasis particularly.
True
False
Tildrakizumab was the first IL-23/p19 inhibitor exhibiting positive findings in phase-3 clinical trials for treating moderate to severe plaque psoriasis.
True
False
Concerning the pathophysiological mechanism of psoriasis, the interleukin-23 (IL-23) cytokine is considered the "master cytokine" because it resides at the top of the inflammation pathway and as such activates proliferation of pathogenic TH17 cells (T-helper 17 cells), resulting in elaboration of pro-inflammatory cytokines (including IL-17).
True
False
Tildrakizumab binds selectively to the p23 subunit thus inhibiting release of pro-inflammatory cytokines as well as chemokines which mediate epidermal hyperplasia, kerotinocytes immune activation and tissue inflammation characteristic of psoriasis.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Ruggiero A Picone V Martora F Fabbrocini G
Menga M Guselkumab, Risankizumab (Skyrizi), Tildrakizumab (Ilumya)
in the Managementof Psoriasis: A Review of the Real-World
Evidence Clinical, Cosmetic and Investigational Dermatology
2022: 15 1649-1658.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392468/
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 25 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 76 Drug Therapy for Rheumatoid Arthritis
Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
Waller DG Sampson A Hitchings Ch 38 The
Immune Response and Immunosuppressant Drugs
Medical Pharmacology & Therapeutics 6e Elsevier 2022
Waller DG Sampson A Hitchings Ch 30
Rheumotoid Arthritis, Other Inflammatory Arthrides and
Osteoarthritis Medical Pharmacology & Therapeutics 6e
Elsevier 2022
